Introduction {#sec1}
============

Somatic stem cells govern the development, maintenance, and regeneration of tissues, and their dysregulation is associated with diverse pathologies, including cancer. Given the significance of these cells both biologically and therapeutically, it is critical to define factors and signaling mechanisms that dictate their behavior, including those that define niches capable of promoting the stem cell phenotype in normal and disease settings. However, few such factors have been elucidated, and progress toward this goal has been impeded by the fact that most somatic stem cells, including those of the mammary gland, are rare and difficult to isolate and propagate ex vivo.

The mammary epithelium consists principally of lineage-restricted basal keratin-14-positive (KRT14^+^) myoepithelial cells and keratin-8-positive (KRT8^+^) luminal epithelial cells ([@bib26]). Although recent reports indicate extensive self-renewal within each of these lineage-committed populations ([@bib37]), classic single-cell transplant experiments indicate the presence of rare transplantable bipotent mammary stem cells (MaSCs) in the mature mammary gland ([@bib30]). These cells can be significantly enriched through the use of cell-surface marker combinations such as CD24 and CD49f ([@bib35]). However, the functional significance of such markers to stem cell biology is often unclear, and the resulting enrichment generally remains too low to discern core molecular determinants of the stem cell state from the population at large.

In an effort to circumvent these challenges, we recently characterized a highly enriched population of stem cells from murine embryonic mammary rudiments ([@bib33]). The greater purity of these fetal mammary stem cells (fMaSC) relative to their adult counterparts makes them particularly useful in the study of MaSC biology. Interestingly, we found that fMaSCs share gene expression features with certain aggressive human breast cancers that are not shared between enriched populations of adult MaSCs and the same breast cancers. This distinction may reflect intrinsic differences between the fetal and adult MaSCs or differential heterogeneity in the stem cell-enriched populations used for profiling. Alternatively, this observation may be due to critical differences in the tissue contexts from which these cells are derived, a possibility consistent with prior reports indicating an important role for microenvironmental factors in establishing and maintaining the stem cell competence of both fetal and adult mammary cells ([@bib24; @bib33; @bib36]). However, the ability of specific factors to promote the MaSC phenotype has rarely been directly demonstrated.

CRIPTO (CR-1, *TDGF1*) is an oncofetal, GPI-anchored/secreted signaling protein that plays key roles as a stem cell regulator ([@bib1; @bib6; @bib16; @bib25]). CRIPTO is dynamically expressed during mammary gland development ([@bib5; @bib20]) and in breast cancer ([@bib11]) but has not been previously examined in the context of MaSCs. CRIPTO promotes proliferation, invasion, and migration of mammary epithelial cell lines in vitro, whereas its overexpression in the mouse mammary gland promotes excessive ductal branching, hyperplasia, and latent tumor growth ([@bib29]). Although the relevant molecular and cellular mechanisms for these effects remain to be determined, CRIPTO impacts multiple signaling pathways associated with stem cells and oncogenesis, including transforming growth factor β (TGF-β), phosphatidylinositol 3-kinase (PI3K), WNT, and NOTCH ([@bib29]). Two distinct CRIPTO signaling activities have been best characterized: (1) a coreceptor function in which CRIPTO modulates signaling of TGF-β ligands such as NODAL that signal via SMAD2/3 activation and (2) a growth-factor-like activity in which soluble CRIPTO activates SRC/mitogen-activated protein kinase/PI3K pathways in a TGF-β pathway-independent manner ([@bib4; @bib12]). Both of these signaling activities require CRIPTO binding to cell-surface GRP78, an HSP70 family member that localizes to the surfaces of stem cells and tumor cells ([@bib12; @bib19; @bib25; @bib31]).

Here, we investigate CRIPTO's ability to regulate primary fetal and adult mammary stem/progenitor cells using a series of ex vivo culture and mammary gland reconstitution experiments. We develop an antagonist that selectively blocks the growth factor-like signaling of soluble CRIPTO without affecting its cell-surface coreceptor activity, and we use this reagent to demonstrate that soluble CRIPTO maintains the MaSC state ex vivo. We further identify cell-surface GRP78 as a determinant of CRIPTO responsiveness and critical functional marker in fetal and adult MaSCs.

Results {#sec2}
=======

An ALK4-Based Antagonist Inhibits Growth-Factor-like Effects of Soluble CRIPTO on Mammary Epithelial Cells {#sec2.1}
----------------------------------------------------------------------------------------------------------

We developed a CRIPTO antagonist in order to test if CRIPTO signaling is required for the maintenance of MaSCs. We took advantage of the CRIPTO binding properties of the extracellular domain (ECD) of the ACTIVIN/NODAL type I receptor ALK4 ([@bib4; @bib12; @bib41]) and the fact that a leucine to alanine substitution at amino acid 75 (L75A) disrupts ALK4/ACTIVIN binding without affecting ALK4 binding to CRIPTO ([@bib18]). Although the L75A mutation does not guarantee complete specificity of ALK4 ECD binding to CRIPTO, we reasoned that this substitution should increase the selectivity of their interaction. We previously showed that a kinase-deleted ALK4^L75A^ protein blocks CRIPTO effects on ACTIVIN and NODAL signaling ([@bib18]), leading us to hypothesize that a soluble version of the ALK4^L75A^ ECD would similarly block CRIPTO signaling. To test this, we fused an N-terminally Flag-tagged ALK4-ECD^L75A^ to the Fc region of human immunoglobulin G (ALK4^L75A^-Fc). We purified the recombinant protein from conditioned media using affinity chromatography and confirmed its ability to bind CRIPTO in solution ([Figures S1](#app2){ref-type="sec"}A--S1D and [Supplemental Experimental Procedures](#app2){ref-type="sec"} available online).

Using the CRIPTO-responsive human mammary epithelial MCF10A cell line, we find that ALK4^L75A^-Fc effectively inhibits binding of soluble CRIPTO to intact cells and blocks CRIPTO-dependent augmentation of AKT phosphorylation ([Figures 1](#fig1){ref-type="fig"}A and 1B). This effect appears to be specific, because ALK4^L75A^-Fc only blocks CRIPTO-dependent AKT phosphorylation, whereas a PI3K inhibitor (LY 294002) blocks detection of both CRIPTO-induced and basal phospho-AKT ([Figure 1](#fig1){ref-type="fig"}B). As expected, and in contrast to CRIPTO-independent ACTIVIN A signaling, NODAL treatment induces SMAD2 phosphorylation in MCF10A cells stably transduced with CRIPTO lentivirus (MCF10A-CR), but not in control cells transduced with empty vector (MCF10A-V) ([Figure 1](#fig1){ref-type="fig"}C). Both NODAL and ACTIVIN A signal via ALK4, and SMAD2 phosphorylation in response to each ligand is blocked by the ALK4/5/7 kinase inhibitor SB 431542 ([Figure 1](#fig1){ref-type="fig"}C). ALK4^L75A^-Fc treatment, on the other hand, has no effect on ACTIVIN A-induced SMAD2 phosphorylation ([Figure 1](#fig1){ref-type="fig"}C), consistent with our previous demonstration that the ALK4^L75A^ mutation blocks ACTIVIN A binding ([@bib18]). Surprisingly, however, ALK4^L75A^-Fc treatment also has no discernible effect on CRIPTO-dependent NODAL signaling in MCF10A-CR cells ([Figure 1](#fig1){ref-type="fig"}C) or on CRIPTO-dependent NODAL induction of a SMAD2-responsive luciferase reporter in 293T cells ([Figure S1](#app2){ref-type="sec"}E). This failure of ALK4^L75A^-Fc to block CRIPTO coreceptor activity is consistent with our inability to detect ALK4^L75A^-Fc binding on the surface of intact CRIPTO-overexpressing 293T cells ([Figure S1](#app2){ref-type="sec"}F).

MCF10A-CR cells secrete CRIPTO ([Figure S2](#app2){ref-type="sec"}A) and have elevated levels of PI3K/AKT signaling relative to MCF10A-V cells ([Figure S2](#app2){ref-type="sec"}B), leading us to test if ALK4^L75A^-Fc inhibits autocrine/paracrine CRIPTO growth factor activity in these cells. We use live-cell time-course and time-lapse microscopy, respectively, to track proliferation and migration of MCF10A-CR cells and control cells (MCF10A-V). MCF10A-CR cells accumulate more rapidly than MCF10A-V cells ([Figure 1](#fig1){ref-type="fig"}D), consistent with our previous findings ([@bib19]), and these CRIPTO expressing cells also have enhanced migration relative to control cells ([Figure 1](#fig1){ref-type="fig"}E). Treatment with ALK4^L75A^-Fc inhibits the CRIPTO-dependent increases in growth ([Figure 1](#fig1){ref-type="fig"}D) and motility ([Figure 1](#fig1){ref-type="fig"}E; [Figure S2](#app2){ref-type="sec"}C; [Movies S1](#mmc3){ref-type="supplementary-material"}, [S2](#mmc4){ref-type="supplementary-material"}, [S3](#mmc5){ref-type="supplementary-material"}, and [S4](#mmc6){ref-type="supplementary-material"}). The inhibitory effects of ALK4^L75A^-Fc treatment on CRIPTO-dependent migrational velocity and persistence are similar to those of GRP78 antibody (N-20) ([Figure 1](#fig1){ref-type="fig"}E; [Figure S2](#app2){ref-type="sec"}C) that we previously showed blocks CRIPTO/GRP78 binding ([@bib19]).

We also analyzed the effects of CRIPTO signaling and antagonism on MCF10A cells in 3D culture in the presence or absence of the reconstituted basement membrane Matrigel. Although suspension cultures have been widely used to measure the production of multicellular mammary epithelial structures called "mammospheres" ([@bib9]), Matrigel-containing mammary epithelial cultures promote the formation of differentiated, polarized acinar structures from MCF10A cells and multilayered, multilineage organoids from primary mammary epithelial stem cells ([@bib7; @bib33]). MCF10A-CR cells accumulate more rapidly than MCF10A-V cells in free-floating suspension cultures, where they exhibit a greater proportion of cells with 2N-4N DNA content indicative of cycling S phase cells ([Figure 1](#fig1){ref-type="fig"}F; [Figures S2](#app2){ref-type="sec"}D and S2E). The growth promoting effects of CRIPTO under these conditions are blocked by treatment with ALK4^L75A^-Fc or LY 294002, but not SB 431542 ([Figure S2](#app2){ref-type="sec"}D). We used methylcellulose immobilization of cells in suspension cultures to measure the size of individual spheres ([Figures 1](#fig1){ref-type="fig"}G and 1H). Consistent with the increased cell numbers observed in free-floating cultures, immobilized MCF10A-CR cells form larger, more numerous mammospheres than MCF10A-V cells, and the increased growth of the CRIPTO-expressing cells is again blocked by ALK4^L75A^-Fc and LY 294002, but not by SB 431542 ([Figure 1](#fig1){ref-type="fig"}H). CRIPTO overexpression similarly promotes MCF10A colony growth in Matrigel, and this is inhibited by treatment with ALK4^L75A^-Fc, whereas treatment of these cultures with NODAL neither augments CRIPTO-induced growth nor overcomes ALK4^L75A^-Fc -mediated inhibition of CRIPTO-induced growth ([Figure S2](#app2){ref-type="sec"}F). Altogether, these results indicate that soluble CRIPTO promotes proliferation and migration of mammary epithelial cells and that this can be blocked by ALK4^L75A^-Fc.

CRIPTO/GRP78 Expression and Function in fMaSCs {#sec2.2}
----------------------------------------------

Our data show that MCF10A cells respond to soluble CRIPTO signaling in multiple contexts, including 3D growth assays that are similar to those used previously to evaluate stem cell-like cellular behaviors ([@bib9]). We also previously demonstrated that soluble CRIPTO activates the PI3K/AKT pathway in MCF10A cells by binding to cell-surface GRP78 ([@bib19]). These findings, together with reports that CRIPTO and GRP78 cooperatively regulate stem cell function in other contexts, prompted us to test if CRIPTO and GRP78 are expressed in murine mammary tissue and if the CRIPTO/GRP78 pathway is operative in primary mammary stem/progenitor cells. We first investigated the pattern of CRIPTO and GRP78 expression in embryonic day 18.5 (E18.5) mouse mammary rudiments, because they provide a rich source of robust stem cell activity ([@bib33]). We find GRP78 to be expressed throughout the mammary rudiment, with the most intense and distinct staining coinciding with the burgeoning, arborized mammary epithelium, demarcated here by costaining with antibodies to KRT8 ([Figures 2](#fig2){ref-type="fig"}A and 2B). By contrast, CRIPTO staining is more diffuse and distributed throughout the rudiment, with significant staining in the fetal mammary stroma and areas within and adjacent to the GRP78-positive and KRT8-positive epithelium. Interestingly, we observe intense CRIPTO staining at or near the termini of the arborized mammary rudiment, where it overlaps with both the condensed mesenchyme adjacent to the epithelium and epithelial cells that stain prominently for GRP78 ([Figures 2](#fig2){ref-type="fig"}A and 2B). *CRIPTO* mRNA was detected in fMaSCs but is more highly expressed in a variety of other cell populations isolated from the fetal mammary microenvironment, including putative adipose precursor cells that resist centrifugation during rudiment processing ("Fat"), myeloid cells (Lin^+^CD11b^+^F4/80^+^), and non-myeloid lineage-positive cells (CD11b^−^F4/80^−^) ([Figure 2](#fig2){ref-type="fig"}C). *CRIPTO* message is also present in other stromal cells (fStromal; Lin^−^CD24^low^) that likely include mammary tissue fibroblasts ([Figure 2](#fig2){ref-type="fig"}C). Costaining of the mammary rudiment for the macrophage marker F4/80 confirms colocalization of CRIPTO protein with not only macrophages but also other nonmacrophage stromal components adjacent to the fetal mammary epithelium ([Figure 2](#fig2){ref-type="fig"}D). Thus, CRIPTO is expressed in multiple cell types within the MaSC microenvironment, leading us to reason that soluble secreted CRIPTO may govern fMaSC behavior as an autocrine/paracrine growth factor.

Our previous studies indicating that CRIPTO signals via cell-surface GRP78 led us to test if GRP78 is expressed on the surface of fMaSCs (Lin^−^CD24^high^) and if these cells respond to soluble CRIPTO in a GRP78-dependent manner. We analyzed dissociated cells from E18.5 mammary rudiments by flow cytometry and discovered that \>80% of the fMaSC population is GRP78 positive ([Figure 2](#fig2){ref-type="fig"}E). Furthermore, when we treat fMaSC-derived Matrigel colonies with soluble CRIPTO, we observe increased AKT phosphorylation that is blocked by treatment with ALK4^L75A^-Fc or LY 294002 ([Figure 2](#fig2){ref-type="fig"}F). This increase in AKT phosphorylation is also blocked by N-20, indicating that CRIPTO signals via cell-surface GRP78 in these cells ([Figure 2](#fig2){ref-type="fig"}F). Soluble CRIPTO treatment also increases the proportion of Ki67^+^ cells relative to untreated cells in 2D culture, and this effect was once again blocked by ALK4^L75A^-Fc treatment ([Figure 2](#fig2){ref-type="fig"}G). Thus, multiple cell types within the fetal mammary rudiment produce CRIPTO, and it can act on cells within the fMaSC population.

CRIPTO/GRP78 Signaling Promotes Maintenance of fMaSCs Ex Vivo {#sec2.3}
-------------------------------------------------------------

To explore the consequences of CRIPTO signaling in MaSCs further, we examined its effects on growth, self-renewal, and differentiation in fMaSC cultures. We previously reported that fMaSCs grown in media that promotes their differentiation give rise to a high proportion of bilineage organoids containing both KRT8^+^KRT14^−^ luminal cells and KRT14^+^KRT8^−^ myoepithelial cells by 7--12 days of culture ([@bib33]). At 5 days of culture, organoids grown in this differentiation promoting media typically contain a fraction of cells coexpressing KRT8 and KRT14 ([Figure 3](#fig3){ref-type="fig"}A, top left, yellow arrows, and [Figure 3](#fig3){ref-type="fig"}B). Supplementation of these cultures with CRIPTO or ALK4^L75A^-Fc has opposing effects on the fraction of organoids containing double-positive (KRT8^+^KRT14^+^) cells and on the amount of double-positive area per organoid ([Figure 3](#fig3){ref-type="fig"}A, left panels, and [Figure 3](#fig3){ref-type="fig"}B; [Figures S3](#app2){ref-type="sec"}A and S3B). Specifically, CRIPTO treatment increases the proportion of double-positive area per organoid while ALK4^L75A^-Fc treatment decreases it, suggesting that CRIPTO signaling promotes maintenance of a multipotent phenotype. However, rapid cellular differentiation under these culture conditions prevented us from confirming stem cell activity of resultant colonies by mammary reconstitution analyses (data not shown; [@bib33]).

To address this issue, we developed culture conditions that are better able to produce mammary epithelial colonies including bilineage organoids that also give rise to mammary outgrowths following transplantation. CRIPTO and ALK4^L75A^-Fc also have opposite effects on the stem cell phenotype of fMaSC-derived colonies grown in this stem cell maintenance media ([Figure 3](#fig3){ref-type="fig"}A, right panels, and [Figure 3](#fig3){ref-type="fig"}B). Endogenous CRIPTO is implicated as a stem cell factor in these cultures by the fact that ALK4^L75A^-Fc treatment alone increases the number of keratin single-positive cells discernible per organoid ([Figure 3](#fig3){ref-type="fig"}A, right panels, red arrows). ALK4^L75A^-Fc also significantly increases the amount of single keratin staining area (either KRT14^+^KRT8^−^ or KRT8^+^KRT14^−^) relative to KRT8^+^KRT14^+^ double-positive area per organoid ([Figure 3](#fig3){ref-type="fig"}B; [Figure S3](#app2){ref-type="sec"}B), although some double-positive cells are evident in all organoids in maintenance media following 5 days of culture ([Figures 3](#fig3){ref-type="fig"}A and 3B; [Figure S3](#app2){ref-type="sec"}B).

Although our data indicate that CRIPTO signaling correlates with KRT8+KRT14+ double positivity, the precise relationship between keratin expression and differentiation status in these cultures is uncertain. It is therefore important that CRIPTO signaling also has *functional* stem cell relevance, because treatment with soluble CRIPTO enhanced the ability of fMaSC-derived colonies grown for 5 days in this media to reconstitute mammary glands upon transplantation relative to untreated controls and this CRIPTO effect was attenuated by ALK4^L75A^-Fc ([Figure 3](#fig3){ref-type="fig"}C). Despite the clear effects of CRIPTO signaling on keratin expression and transplantation, treatment with CRIPTO and/or ALK4^L75A^-Fc does not significantly affect overall colony number and size in 5-day cultures ([Figure 3](#fig3){ref-type="fig"}D). However, when cells are serially passaged for three rounds under stem cell maintenance conditions, ALK4^L75A^-Fc treatment substantially reduces colony-forming efficiency and the growth of large colonies (\>100 μm) is almost completely abolished ([Figure 3](#fig3){ref-type="fig"}D). Conversely, addition of CRIPTO can support a round of serial passage of fMaSC-derived cells, even under conditions that strongly favor differentiation ([Figure 3](#fig3){ref-type="fig"}D). We note that clonogenicity of fetal mammary cells was recently shown to be enhanced by unidentified factors secreted by 3T3 fibroblasts in coculture ([@bib24]). We find that 3T3 cells express CRIPTO protein ([Figure S3](#app2){ref-type="sec"}D) and that their ability to enhance clonogenicity of fetal mammary cells in coculture can be partially blocked by treatment with either ALK4^L75A^-Fc or CRIPTO antibodies ([Figure S3](#app2){ref-type="sec"}E). This result is consistent with our results using recombinant proteins and further highlights the potential for non-cell-autonomous CRIPTO regulation of fMaSCs.

GRP78 Is a Critical Functional Marker and Cell-Surface Determinant of CRIPTO-Responsive MaSCs {#sec2.4}
---------------------------------------------------------------------------------------------

We examined CRIPTO and GRP78 expression in the adult mammary gland and identified marked immunoreactivity for both proteins that overlaps with the morphologically distinct mammary ductal epithelium and adjacent adipose tissue ([Figure 4](#fig4){ref-type="fig"}A). Immunofluorescent colocalization studies confirm overlapping CRIPTO and GRP78 staining in these cell types, including elevated staining in adipose and a subset of mammary epithelial cells ([Figure 4](#fig4){ref-type="fig"}B). To determine whether adult MaSCs require GRP78, we used CRE-mediated recombination and excision of GRP78 alleles together with mammary gland reconstitution experiments. In these experiments, cells harboring CRE-expressing virus failed to reconstitute mammary ductal trees in each of nine transplant attempts (zero out of nine), while an equivalent number of cells transduced with control virus robustly repopulate the gland (three out of three) ([Figure 4](#fig4){ref-type="fig"}A). Furthermore, cells isolated from control outgrowths exhibit cell-surface GRP78 and contain both the luminal and myoepithelial fractions ([Figure S4](#app2){ref-type="sec"}C). In contrast, we only occasionally recover a low number of presumptive mammary epithelial cells from transplants of GRP78Fl/Fl cells infected with CRE virus. These cells appear restricted to the mature luminal fraction, lack detectable cell-surface GRP78, and do not give rise to colonies when cultured in vitro ([Figure S4](#app2){ref-type="sec"}A; data not shown). These data indicate that GRP78 is required for MaSC activity as measured by transplantation assays.

Next, we sought to examine the role of cell-surface GRP78 as an adult MaSC marker and as a MaSC regulator specifically in its capacity as a mediator of CRIPTO signaling. We isolated CD24-positive mammary epithelial cells with either high (GRP78^high^) or low (GRP78^low^) levels of cell-surface GRP78 from wild-type mice ([Figure 4](#fig4){ref-type="fig"}D, left panel). A substantial portion of adult mammary epithelial cells was GRP78^high^ (19.4% ± 3.4% of the CD24-positive fraction), though the proportion was considerably lower than in fetal mammary epithelia ([Figure 3](#fig3){ref-type="fig"}D). In costained samples, we observe that while the GRP78^high^ population overlaps partially with the previously reported luminal colony-forming cell (CFC) and myoepithelial (MYO) populations, it overlaps most precisely with the stem cell-enriched CD24^med^CD49f^high^ mammary repopulating unit (MRU) fraction ([Figure 4](#fig4){ref-type="fig"}D, right panel) ([@bib35]). While cells from both the GRP78^high^ and GRP78^low^ fractions produce clonal outgrowths in Matrigel culture, those derived from the GRP78^high^ population are much more likely to give rise to colonies containing multiple cell layers ([Figure 4](#fig4){ref-type="fig"}E; organoids) and to stain positive for both KRT14 and KRT8 ([Figure 4](#fig4){ref-type="fig"}F; [Figure S4](#app2){ref-type="sec"}B). In these assays, the most frequently observed and morphologically distinguishable colony types include those that appear luminal, composed of a single peripheral cell layer surrounding an open lumen, small myoepithelial colonies (usually \< 16 cells), and distinctive, multilayered organoids containing both luminal and myoepithelial cell types ([Figures 4](#fig4){ref-type="fig"}E and 4F) ([@bib33; @bib35]). Importantly, these morphologically distinct colony types are produced in cultures both when single cells were plated in individual wells ([Figure 4](#fig4){ref-type="fig"}E) and when cells are plated at single-cell densities (1,000 cells per 0.32 cm^2^) ([Figure 4](#fig4){ref-type="fig"}F; data not shown) ([@bib33]). Thus, the substantially higher proportion of organoids and KRT14^+^KRT8^+^ double-positive colonies formed from the GRP78^high^ population ([Figures 4](#fig4){ref-type="fig"}E and 4F; [Figure S4](#app2){ref-type="sec"}B) suggests that the GRP78^high^ population is enriched for bipotent stem/progenitor cells. In contrast, GRP78^low^ cells predominantly give rise to small myoepithelial (KRT14^+^KRT8^−^) or monolayered luminal (KRT14^−^KRT8^+^) outgrowths ([Figures 4](#fig4){ref-type="fig"}E and 4F; [Figure S4](#app2){ref-type="sec"}B).

As an independent criterion for assessing the stem cell content of the GRP78^high^ population, we transplanted CD24^med^GRP78^high^ and CD24^med^GRP78^low^ mammary epithelial cell populations into cleared mammary fat pads at limiting dilutions. The results clearly indicate that the CD24^med^GRP78^high^ cells reconstitute mammary glands more efficiently the CD24^med^GRP78^low^ cells ([Figure 4](#fig4){ref-type="fig"}G; [Figures S4](#app2){ref-type="sec"}C--S4E). We estimate the frequency of mammary gland-reconstituting units to be approximately 1/26 in the GRP78^high^ cells (90% confidence interval \[CI\], 1/15--45.4; extreme limiting dilution analysis \[ELDA\]) versus approximately 1/152 in the GRP78^low^ population (90% CI, 1/67.0--346.2; ELDA) ([Figure 4](#fig4){ref-type="fig"}G; [Figure S4](#app2){ref-type="sec"}E). This correlates with a significant enrichment (p \< 0.01; ELDA) of stem cell activity in the GRP78^high^ fraction relative to the GRP78^low^ cells ([Figure 4](#fig4){ref-type="fig"}G; [Figures S4](#app2){ref-type="sec"}C--S4E). Outgrowths from transplanted GRP78^high^ cells resemble endogenous mammary glands in FACS analyses including the presence of GRP78^high^ cells within the CD24 expressing mammary epithelium ([Figure S4](#app2){ref-type="sec"}F). Significantly, the self-renewal potential of these cells is evident in their capacity to reconstitute fully arborized mammary epithelial outgrowths in tertiary transplants that respond normally to pregnancy ([Figure S4](#app2){ref-type="sec"}G). We also identify a diffuse, small, and variable population of GRP78 "superpositive" (GRP78^high**+**^) cells with intermediate performance in stem cell assays ([Figures S4](#app2){ref-type="sec"}D and S4E).

Because CRIPTO signaling promotes serial passage of fMaSCs ex vivo ([Figure 3](#fig3){ref-type="fig"}D), we tested the effects of this pathway on cultures of adult GRP78^high^ and GRP78^low^ mammary epithelial populations. Consistent with its greater enrichment for cells with a bipotent stem cell phenotype ([Figures 4](#fig4){ref-type="fig"}E--4G; [Figure S4](#app2){ref-type="sec"}B), the GRP78^high^ population exhibits greatly enhanced potential for serial colony formation relative to GRP78^low^ cells, especially over increasing serial passage number in Matrigel ([Figure 4](#fig4){ref-type="fig"}H; [Figure S4](#app2){ref-type="sec"}H). Furthermore, serial passage of GRP78^high^ cells is significantly enhanced by CRIPTO treatment ([Figure 4](#fig4){ref-type="fig"}H) and, similar to what was observed with fMaSCs, serial colony formation of adult GRP78^high^ cells is also inhibited by ALK4^L75A^-Fc treatment, suggesting that endogenous soluble CRIPTO maintains the self-renewal potential of these cells. By contrast, GRP78^low^ cells are largely refractory to treatment with CRIPTO or ALK4^L75A^-Fc ([Figure 4](#fig4){ref-type="fig"}H), consistent with a requirement for surface GRP78 for CRIPTO signaling ([@bib19]). Together, these data support a role for soluble CRIPTO in maintaining the stem cell phenotype of GRP78^high^ mammary epithelial cells.

The data are consistent with a model ([Figure 4](#fig4){ref-type="fig"}I) in which surface GRP78 is a functional MaSC marker. In this model, the most undifferentiated MaSC state depends on endogenous CRIPTO signaling, because treatment with ALK4^L75A^-Fc leads to loss of multipotency and eventual rundown of self-renewal in serial passage. In addition, a subset of cells, at least in the adult context, lacks endogenous CRIPTO but can respond to exogenous soluble CRIPTO with increased serial clonogenicity or self-renewal. Thus, according to this model, CRIPTO treatment shifts cells to a more primitive, stable, or competent stem cell state while ALK4^L75A^-Fc treatment makes them susceptible to commitment and differentiation.

Discussion {#sec3}
==========

Extracellular signaling factors play critical roles in regulating the balance between stem cell self-renewal and differentiation ([@bib17; @bib34]). In the present study, we identify CRIPTO as one such factor that promotes multipotency and maintains gland reconstitution potential of mammary stem/progenitor cells ex vivo. We also show that the CRIPTO cell-surface receptor GRP78 is required for MaSC activity and CRIPTO responsiveness. Thus, CRIPTO and GRP78 are shared determinants of both fetal and adult mammary stem/progenitor cells pointing to a developmentally conserved role for the CRIPTO/GRP78 pathway in maintenance of the MaSC state.

ALK4^L75A^-Fc Identifies Soluble CRIPTO as a MaSC Factor {#sec3.1}
--------------------------------------------------------

ALK4^L75A^-Fc selectively targets soluble CRIPTO and blocks CRIPTO-induced PI3K/AKT signaling, indicating that CRIPTO's growth factor-like activity is essential for maintenance of MaSC properties in the contexts we analyzed. [@bib25] similarly showed that soluble CRIPTO regulates hematopoietic stem cells (HSC) via the PI3K/AKT pathway independent of SMAD2/3 signaling. However, although our results uncover a critical role for soluble CRIPTO growth-factor-like signaling in regulating MaSC behavior, they do not exclude a role for CRIPTO coreceptor function. Indeed, NODAL, which requires CRIPTO or a related coreceptor, may act on fMaSCs during development in vivo, because it is expressed in fetal mammary stroma ([@bib33]).

ALK4^L75A^-Fc treatment alone is sufficient to cause MaSC differentiation and loss of self-renewal potential ex vivo, suggesting that endogenously secreted CRIPTO sustains the clonogenicity and multipotency of mammary epithelial cells in maintenance media and in 3T3 fibroblast cocultures. Consistent with this, CRIPTO treatment inhibits lineage commitment of cells in organoid culture and increases their serial colony formation and transplantation capacity. Therefore, CRIPTO acts as an extrinsic, soluble regulator of MaSC function in vitro, raising the possibility that it may function similarly as an autocrine/paracrine stem cell factor in vivo. In support of such a role, we show that GRP78 is prominently expressed throughout the ductal epithelium within the fetal mammary rudiment while CRIPTO is concentrated near the termini of the epithelial tree and the mesenchyme surrounding these termini where stem cell activity may be focused ([@bib21]). *CRIPTO* expression is low in fMaSCs but higher in a variety of nonepithelial cells of the mammary rudiment such as fat cells and macrophage/myeloid cells that could mark potential niche sources of secreted CRIPTO. Adipose tissue has been previously reported to express CRIPTO ([@bib2]) and constitutes the natural environment for growth and development of the mammary ductal epithelium ([@bib38]). Myeloid cells, including macrophages, may also provide soluble CRIPTO for stem cell regulation, because they comprise important niche components in other systems and are required for effective mammary reconstitution ([@bib10; @bib14]).

Cell-Surface GRP78 Is a Developmentally Conserved Marker of Fetal and Adult MaSCs {#sec3.2}
---------------------------------------------------------------------------------

Our data identify cell-surface GRP78 as an enrichment marker of mammary stem/progenitor cells. CRIPTO and GRP78 are coexpressed in the adult mammary gland, and cell-surface GRP78 correlates with the stem cell-surface markers CD24 and CD49f ([@bib35]). Bipotent stem/progenitor cells, though rare in the adult gland, are relatively plentiful in the sorted GRP78^high^ population. GRP78^high^ cells are also selectively responsive to CRIPTO signaling, because CRIPTO and ALK4^L75A^-Fc had opposing effects on their serial colony growth and neither treatment significantly affected the GRP78^low^ population. Interestingly, the percentage of GRP78^high^ cells is greater in the fetal than in the adult mammary gland, in agreement with the larger percentage of stem cells in the fetal mammary gland than in the adult ([@bib33]). However, despite its ability to augment serial colony formation in cultures derived from GRP78^high^ adult cells, CRIPTO treatment only has a modest effect on serial colony formation of fMaSCs in maintenance media. It is possible that CRIPTO growth-factor-like signaling is maximally activated in newly isolated fetal, but not adult, stem cells. This would explain the profound ability of the CRIPTO antagonist ALK4^L75A^-Fc to inhibit fMaSC maintenance despite the lack of a more profound effect of CRIPTO treatment on these cells. This activity appears to be more rapidly lost in stronger differentiation-promoting contexts, unveiling a clear effect of exogenous CRIPTO in sustaining a limited capacity for serial passage.

CRIPTO/GRP78 Signaling as a General Regulator of the Stem Cell State {#sec3.3}
--------------------------------------------------------------------

CRIPTO is an established regulator of embryonic stem cells and induced pluripotent stem cells ([@bib6]), whereas GRP78 is a necessary mediator of CRIPTO signaling in human embryonic stem cells ([@bib19]) and promotes survival and proliferation of the murine inner cell mass cells that are precursors of murine embryonic stem cells ([@bib23]). In the adult, GRP78 was recently reported to be essential for maintenance of adult intestinal stem cells ([@bib15]) and conditional deletion of GRP78 in the hematopoietic system suppressed PI3K activity and decreased HSC number ([@bib39; @bib40]). Furthermore, CRIPTO was shown to be a hypoxic niche-associated factor that maintains the stem cell state and transplantability of GRP78^high^ HSCs cultured ex vivo ([@bib25]). Although the mechanistic basis of CRIPTO/GRP78 signaling is still emerging, it has been shown that cell-surface localization of GRP78 often correlates with its overall expression level and occurs under stress conditions in which GRP78 is induced ([@bib43]). Therefore, although the stem cell niche remains poorly defined in the mammary gland, our results suggest that conditions known to increase the levels of GRP78 and/or CRIPTO such as hypoxia, nutrient deprivation, and endoplasmic reticulum stress could impact stem cell maintenance, expansion, and induction during normal mammary gland development and in homeostasis. Similarly, other signals from within the MaSC microenvironment likely intersect with CRIPTO and GRP78. For instance, Wnt signaling induces CRIPTO expression ([@bib28]) and has been reported to promote MaSC self-renewal in vitro ([@bib42]).

Our recent demonstration that fMaSCs share a high degree of similarity with certain human breast cancers ([@bib33]) is consistent with other evidence suggesting that tumor initiation, aggressiveness, and recurrence correlate with developmentally primitive states that are associated with cellular plasticity and increased stem cell disposition ([@bib3; @bib27; @bib32]). The results presented here show that CRIPTO/GRP78 signaling increases proliferation and maintains the potency of MaSCs ex vivo and raise the possibility that this pathway may be involved in promoting stem cell-like states in cancer, especially because expression of CRIPTO and GRP78 has been correlated with breast cancer progression and decreased patient survival ([@bib8; @bib11; @bib22]). The stress-related cues that increase the expression of CRIPTO and GRP78 are prevalent in cancer and might specifically promote stem cell properties via increased CRIPTO/GRP78 signaling ([@bib25; @bib43]). In this regard, the ALK4^L75A^-Fc CRIPTO antagonist described here would have potential as a stem cell-directed cancer therapeutic.

Experimental Procedures {#sec4}
=======================

See [Supplemental Information](#app2){ref-type="sec"} for additional details.

Reagents {#sec4.1}
--------

ALK4^L75A^-Fc was produced in 293T cells and purified by sequential protein-A and Flag affinity chromatography from conditioned media. Recombinant mouse CRIPTO (R&D Systems) was iodinated as previously described ([@bib19]). The following antibodies were used: CRIPTO (Abcam), GRP78 (N-20, Santa Cruz Biotechnology), KRT14 (AF-64, Covance), KRT8 (Troma-1, DSHB), F4/80 (BM8, eBioscience), Ki67 (B56, BD). Polyclonal rabbit antibodies directed against amino acids 19--39 of human GRP78 or amino acids 81--97 of mouse CRIPTO were produced in-house (see [Supplemental Information](#app2){ref-type="sec"}). The A3-luciferase reporter assay has been described previously ([@bib13; @bib18]). GRP78 floxed mice were provided by Amy Lee (University of Southern California).

Media {#sec4.2}
-----

MCF10A media was composed of Dulbecco's modified Eagle's medium/F12 with 5% horse serum, 10 μg/ml insulin, 20 ng/ml epidermal growth factor, 100 ng/ml cholera toxin, 0.5 μg/ml hydrocortisone, and 10 μg/ml ciprofloxacin. Maintenance media was composed of MCF10A with 1× B27 supplement (Invitrogen). Differentiation media was composed of Epicult-B mouse media containing B supplement (Stem Cell Technologies), recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, and heparin, as previously described ([@bib33]), with ciprofloxacin 10 μg/ml.

Cell Preparation and Culture {#sec4.3}
----------------------------

All animal care and procedures were approved and monitored by an Institutional Animal Care and Use Committee. MCF10A cells were cultured free floating in CnT-27 media or immobilized in MCF10A media with 2% Matrigel or 1% methylcellulose. Primary cells were prepared, sorted, cultured, and stained as previously described ([@bib33]) using the indicated media. 3T3 cocultures were adapted from [@bib24].

Assays {#sec4.4}
------

Proliferation in 2D was quantified on a Celigo microplate cytometer (Cyntellect). Migrational dynamics were tracked using time-lapse microscopy and Metamorph Imaging software on 2D cultures on Matrigel. DNA content was measured by Hoechst staining. mRNA abundance was measured using Superscript III (Life Technologies) and TaqMan assays Mm03024051_g1 and Mm01324427_m1 (Applied Biosciences). Mammary transplantation analyses were conducted as previously described ([@bib33]). Organoid transplants used 20 organoids each by dilution. Western blotting and quantitation of cell-surface proteins by intact cell ELISA have also been previously described ([@bib13; @bib18]).

Statistics {#sec4.5}
----------

Data are presented as means and SDs with p values derived from pairwise Student's t tests, except where otherwise noted. ELDA (<http://bioinf.wehi.edu.au/software/elda>) was used to estimate stem cell frequencies.

Supplemental Information {#app2}
========================
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![ALK4^L75A^-Fc Inhibits Growth-Factor-like Effects of CRIPTO on Immortalized Human Mammary Epithelial Cells\
(A) ALK4^L75A^-Fc (10 μg/ml) inhibits binding of ^125^I-CRIPTO to native MCF10A cells. Data from one of two independent experiments using three technical replicates are shown, with SDs.\
(B) Phospho-AKT (Ser 473) or total AKT western blots on lysates from MCF10A cells treated with soluble CRIPTO (300 ng/ml), ALK4^L75A^-Fc, and PI3K inhibitor LY 294002 (10 μM) as indicated.\
(C) Phospho-SMAD2 and SMAD2/3 western blots on MCF10A cells stably transduced with CRIPTO-Flag virus (MCF10A-CR) or control virus (MCF10A-V) and treated as indicated with ACTIVIN A (1 nM), NODAL (30 nM), ALK4^L75A^-Fc, and the ALK4/5/7 inhibitor SB 431542 (10 μM).\
(D) Time course showing that MCF10A-CR cells accumulate more rapidly than MCF10A-V cells in 2D culture. Treatment with ALK4^L75A^-Fc selectively inhibits growth of MCF10A-CR cells. ^∗^p \< 0.01. Triplicate wells in a representative experiment are shown, with SDs.\
(E) MCF10A-CR cells are more migratory than MCF10A-V cells. The CRIPTO-dependent increase in migrational velocity and persistence is blocked by ALK4^L75A^-Fc treatment or a GRP78 neutralizing antibody (N-20). ^∗∗^p \< 0.01, two-way ANOVA. Data from ≥50 individual cells from three fields of view per condition in one experiment (of two performed) are shown, with SDs.\
(F) Suspension cultures of MCF10A-V and MCF10A-CR cells 11 days after seeding in 24-well plates. MCF10A-CR cells grow more rapidly than MCF10A-V cells in suspension culture, and this growth advantage is inhibited by ALK4^L75A^-Fc treatment.\
(G) MCF10A-CR cells produce larger and more plentiful colonies than MCF10A-V cells when grown in immobilizing methylcellulose suspension cultures, and ALK4^L75A^-Fc treatment blocks this CRIPTO-dependent growth. Bar represents 30 μm.\
(H) Colony growth was significantly reduced by either ALK4^L75A^-Fc treatment or PI3K inhibition (LY 294002 10 μM), but not by treatment with SB 431542. ^∗^p \< 0.05. Two independent experiments with duplicate wells in each are tabulated, with SDs. SB 431542 treatment increased colony number, but not mean size, of MCF10A-V cells.\
See also [Figures S1](#app2){ref-type="sec"} and [S2](#app2){ref-type="sec"}.](gr1){#fig1}

![Expression of CRIPTO and GRP78 in the Fetal Mammary Rudiment and Responsiveness of fMaSCs to Soluble CRIPTO\
(A and B) Whole-mount E18.5 fetal mammary rudiment demarcated with immunofluorescence staining for KRT8 (blue) or DAPI (white) and costained for CRIPTO (green) and GRP78 (red) (right). (A, i--iii) control rudiment stained with KRT8 and isotype-matched controls for GRP78 and CRIPTO. Scale bar represents 200 μm (A) or 50 μm (B).\
(C) CRIPTO is expressed in the fMaSC population and stromal cells as measured by RT-PCR. A total of 150 rudiments were pooled and assayed in technical triplicates, with SDs.\
(D) CRIPTO staining colocalizes with F4/80 staining (arrows) adjacent to mammary epithelium demarcated by KRT8 staining (blue).\
(E) Flow cytometric analysis of fetal mouse mammary cells stained with CD24, GRP78, and isotype control antibodies as indicated. The percentage of the CD24^high^ population also positive for GRP78 is shown.\
(F) Phospho-AKT staining in serum-starved, fMaSC-derived organoids treated as indicated with soluble CRIPTO (300 ng/ml), ALK4^L75A^-Fc (10 μg/ml), LY 294002 (10 μM), or N-20 (2 μg/ml). Scale bar represents 50 μm.\
(G) 2D fMaSC cultures were treated with CRIPTO (400 ng/ml) and/or ALK4^L75A^-Fc (10 μg/ml) as indicated and stained with Ki67 antibody and DAPI. Scale bar represents 50 μm, and inset represents 10 μm.](gr2){#fig2}

![CRIPTO Promotes Maintenance of fMaSCs\
(A) Sphere-bisecting confocal cross sections of day 5, fMaSC-derived colonies grown in Matrigel and stained with KRT8 (green) and KRT14 (red). Colonies were grown in differentiation media or maintenance media with soluble CRIPTO (0.33 μg/ml) or ALK4^L75A^-Fc (10 μg/ml) as indicated. Yellow arrows indicate KRT8^+^KRT14^+^ double-positive cells. Red arrows indicate lineage-committed KRT14 single-positive cells. Control represents the same isotype. Scale bar represents 100 μm.\
(B) KRT8 and KRT14 staining was quantified from images and is represented as the percent KRT8^+^KRT14^+^ double-labeled area per organoid. The percentage of organoids containing KRT8^+^KRT14^+^ double-labeled cells is also indicated. Results of three independent representative experiments are shown.\
(C) Mammary gland repopulation efficiency of first-generation colonies grown in Matrigel-containing maintenance media culture with soluble CRIPTO and/or ALK4^L75A^-Fc. Each circle represents one recipient mammary gland. Shaded circles represent ducts extending through \>50% of the fat pad.\
(D) Colony-forming efficiencies (\>100 μm) at first, second, and third passage for fMaSCs grown for 7 days per passage in differentiation or maintenance media with CRIPTO and/or ALK4^L75A^-Fc. Results of three independent experiments (maintenance media) and a representative experiment (differentiation media) were quantified. Triplicate wells were quantified in each. Error bars represent SDs. ^∗^p ≤ 0.01.\
See also [Figure S3](#app2){ref-type="sec"}.](gr3){#fig3}

![GRP78 Is Required for MaSC Activity and Marks a CRIPTO-Responsive Stem Cell-Enriched Population of Adult Mouse Mammary Epithelial Cells\
(A) Immunohistochemical localization of CRIPTO and GRP78 in adult mouse mammary tissue. Inset: secondary antibody alone (2^nd^).\
(B) CRIPTO and GRP78 proteins colocalize in stromal areas including adipose (f, fat) and in epithelial structures (e), where a subset of cells display elevated staining for both markers (white arrows).\
(C) Repopulation rate of de-epithelialized mammary glands inoculated with 500 GRP78-floxed epithelial cells transduced with Ad-CRE/GFP- or Ad-GFP and sorted for GFP. Each circle represents one recipient mammary gland. Filled circles indicate \>50% fat pad filling.\
(D) Flow cytometric analysis of wild-type adult mouse mammary cells stained for CD24 and GRP78 (lineage excluded) indicating the presence of cell-surface GRP78 in adult mammary epithelia and demarcating the GRP78^high^ and GRP78^low^ populations (left). Antibodies to CD49f were also incorporated (right), and cells positive for GRP78 and CD24 were gated to generate a population density graph (red lines) superimposed on the CD24/CD49f staining. The standard positions of the CFC, MYO, and MRU populations ([@bib35]) are indicated.\
(E) Colonies grown from single cells sorted into individual wells in 96-well plates. Luminal, organoid, and myoepithelial morphologies were distinguishable (left). The number of each type of clonal outgrowth deriving from single GRP78^low^ and GRP78^high^ cells in one representative experiment (of three similar experiments) was quantified according to morphology (right).\
(F) Confocal micrographs showing the keratin distribution observed in representative colonies grown from cells sorted using CD24 and GRP78. GRP78^low^ cells predominantly expressed either KRT8 or KRT14, while GRP78^high^ cultures frequently exhibited KRT8^+^KRT14^+^ outgrowths. Representative organoid (i), luminal (ii), and myoepithelial (iii) colonies are shown. Color panels show individual fluorophores separately for the organoid (i, insets). Scale bars represent 100 μm.\
(G) Mammary gland repopulation efficiencies of GRP78^high^ and GRP78^low^ cells represented as in (C) (the data fit a single-hit model; likelihood ratio test p = 0.938; ELDA).\
(H) GRP78^high^ cells are selectively responsive to soluble CRIPTO or ALK4^L75A^--Fc treatment when serially passaged in Matrigel culture. Results of two independent experiments conducted in triplicate are shown, with SDs. Black bracket p \< 0.05; red bracket p \< 0.01.\
(I) Model depicting cooperativity of soluble CRIPTO (sCR) and cell-surface GRP78 in promoting mammary stem cell maintenance. Soluble CRIPTO reinforces a robust primitive epithelial stem cell state, whereas loss of soluble CRIPTO signaling leaves cells vulnerable to differentiation cues and eventual loss of stem cell characteristics such as bipotency (yellow cells) and self-renewal (circular arrow).\
See also [Figure S4](#app2){ref-type="sec"}.](gr4){#fig4}
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